A. P. Jesus-Nunes - The Consciousness Library

Clinical predictors of depressive symptom remission and response after racemic ketamine and esketamine infusion in treatment‐resistant depression

Human Psychopharmacology February 18, 2022 A. P. Jesus-Nunes, Gustavo C. Leal, Fernanda S. Correia-Melo et al. 39 citations

Major depressive disorder (MDD) is a leading cause of disability worldwide and most people do not achieve symptom remission. Treatment‐resistant depression (TRD) is characterized by the failure of at least one adequate trial of a major class of antidepressant, with adequate time and dosage. We aimed to identify clinical predictors of depressive symptom remission and response 24 h and 7 days...

DOI: 10.1002/hup.2836

Trait dissociation as a predictor of induced dissociation by ketamine or esketamine in treatment-resistant depression: Secondary analysis from a randomized controlled trial.

Journal of Psychiatric Research May 8, 2021 Rodrigo P Mello, Mariana V F Echegaray, A. P. Jesus-Nunes et al. 22 citations

Dissociative symptoms are common, possibly severe, side effects associated with the use of ketamine and esketamine in depression. We investigated the relationship between trait dissociation and dissociation induced by ketamine and esketamine used as augmentation therapy in treatment-resistant depression (TRD). Adults with TRD were randomly assigned to receive a single intravenous infusion, with...

DOI: 10.1016/j.jpsychires.2021.05.014

Intravenous arketamine for treatment-resistant depression: open-label pilot study

European Archives of Psychiatry and Clinical Neuroscience February 20, 2020 Gustavo C. Leal, Igor D. Bandeira, Fernanda S. Correia-Melo et al. 257 citations

We aimed to analyze the efficacy and safety of arketamine, the R (−)-enantiomer of ketamine, for treatment-resistant depression (TRD) in humans. Open-label pilot trial, seven subjects with TRD received a single intravenous infusion of arketamine (0.5 mg/kg); primary outcome was change in Montgomery–Åsberg Depression Rating Scale (MADRS) 24 h after. Mean MADRS dropped from 30.7 before infusion...

DOI: 10.1007/s00406-020-01110-5 Full text

Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: A randomized, double-blind, non-inferiority study.

Journal of Affective Disorders November 14, 2019 Fernanda S. Correia-Melo, Gustavo C. Leal, Flávia Vieira et al. 188 citations

BACKGROUND Ketamine and its enantiomers have recently been highlighted as one of the most effective therapeutic options in refractory depression. However, racemic ketamine and esketamine have not been directly compared. The aim of this study is to assess the efficacy and safety of esketamine compared to ketamine in patients with treatment-resistant depression (TRD). METHODS This is a...

DOI: 10.1016/j.jad.2019.11.086

Papers

Clinical predictors of depressive symptom remission and response after racemic ketamine and esketamine infusion in treatment‐resistant depression

Trait dissociation as a predictor of induced dissociation by ketamine or esketamine in treatment-resistant depression: Secondary analysis from a randomized controlled trial.

Intravenous arketamine for treatment-resistant depression: open-label pilot study

Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: A randomized, double-blind, non-inferiority study.